

# Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer

AACR Annual Meeting Chicago IL  
April 25-30, 2025

Poster section 51, Poster board # 4  
Presentation LB422

Sofia Gkountela<sup>1</sup>, William Tahaney<sup>2</sup>, Vasiliki Vafeiadou<sup>1</sup>, Christelle Bianda<sup>1</sup>, Liam Cheeseman<sup>1</sup>, Ambika Singh<sup>1</sup>, Anna Diesslin<sup>1</sup>, Martin Schillo<sup>1</sup>, Sophia Nguyen<sup>2</sup>, Luca Moccia<sup>1</sup>, Christopher King<sup>2</sup>, Yimao Liu<sup>2</sup>, Chao Quan<sup>2</sup>, Bradley DeMarco<sup>2</sup>, Laura Schwander<sup>1</sup>, Vaik Strande<sup>1</sup>, Jessica Alers<sup>2</sup>, Rajiv Narayan<sup>2</sup>, Dave Peck<sup>2</sup>, Sarah Pessa<sup>2</sup>, Samuel Gilberto<sup>1</sup>, John Castle<sup>1</sup>, Filip Janku<sup>2</sup>, Sharon Townson<sup>2</sup>, Markus Warmuth<sup>2</sup>, Magnus Walter<sup>1</sup>, Beatrice Ranieri<sup>1</sup>, Ralph Tiedt<sup>1</sup>, Nina Ilic-Widlund<sup>2</sup>

<sup>1</sup>Monte Rosa Therapeutics AG, WKL-136, Klybeckstrasse 191, 0457 Basel, Switzerland; <sup>2</sup>Monte Rosa Therapeutics Inc., 321 Harrison Ave, Boston, MA 02118, United States

